|
× |
 |
INDIGOTINDISULFONATE SODIUM Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
WEGOVY (semaglutide) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
ZEPOSIA (ozanimod hydrochloride) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
POTASSIUM CHLORIDE Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
VYZULTA (latanoprostene bunod) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
XYWAV (calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
VENCLEXTA (venetoclax) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
GLYCERIN Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
ZYDELIG (idelalisib) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
|
|